Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | NEK2 | P51955 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786708 | 0.83 | GAA (0.52) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL27539882 | 0.77 | ALDH1A1 (0.38) | GAAKMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL9614284 | 0.76 | CHEK1 (0.50) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL19786 | 0.76 | MAPT (0.46) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL113870 | 0.75 | CHEK1 (0.60) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL29707613 | 0.75 | CHEK1 (0.60) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| Fluoride SCHEMBL10978496 | 0.75 | ALDH1A1 (0.36) | GAAKMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL31689542 | 0.74 | CHEK1 (0.79) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL5395552 | 0.74 | MAPT (0.44) | CHEK1NEK2LIMK1DYRK1ACLK4 | |
| SCHEMBL29922382 | 0.74 | CHEK1 (0.79) | CHEK1NEK2LIMK1DYRK1ACLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-6747051-B2 | BLADDER UROGENITAL DISORDERS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-08 | — | — | US | disclosed |
| CN-1471514-A | Novel M-amino-phenylimino-imidazolidone derivatives for treating urinary incontinence | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-01-28 | — | — | CN | disclosed |
| US-20030158420-A1 | m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | disclosed |
| US-6602897-B2 | For example, 2-((2-bromo-3-chloro-5-dimethylamino-6-methylphenyl)imino)imid azolidine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-05 | — | — | US | disclosed |
| EP-1328517-A2 | NOVEL M-AMINO-PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | Boehringer Ingelheim Pharma KG (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-20020161031-A1 | m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-31 | — | — | US | disclosed |
| WO-2002032876-A2 | NOVEL M-AMINO-PHENYLIMINO-IMIDAZOLIDINE DERIVATIVES FOR TREATING URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161031-A1 | m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence | RXFP1, RXFP3, PRMT1 | CHEK1 3272/4885NEK2 2364/4885LIMK1 4477/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CHEK1 2077/4885NEK2 812/4885LIMK1 4113/4885 |
| US-20030158420-A1 | m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence | HRH2, RXFP3, AREG | CHEK1 3338/4885NEK2 1830/4885LIMK1 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.